- Markets
- Healthcare
- HESTERBIO
HESTERBIO
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Hester Biosciences March-Qtr Consol Net Profit Falls
May 17 (Reuters) - Hester Biosciences Ltd HEST.NS:
INDIA'S HESTER BIOSCIENCES LTD MARCH-QUARTER CONSOL NET PROFIT 45.3 MILLION RUPEES VERSUS PROFIT 77.2 MILLION RUPEES
HESTER BIOSCIENCES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 673 MILLION RUPEES VERSUS 564.7 MILLION RUPEES
DIVIDEND OF 8 RUPEES PER SHARE
Source text for Eikon: ID:nBSE6DWGJ5
Further company coverage: HEST.NS
(([email protected];;))
May 17 (Reuters) - Hester Biosciences Ltd HEST.NS:
INDIA'S HESTER BIOSCIENCES LTD MARCH-QUARTER CONSOL NET PROFIT 45.3 MILLION RUPEES VERSUS PROFIT 77.2 MILLION RUPEES
HESTER BIOSCIENCES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 673 MILLION RUPEES VERSUS 564.7 MILLION RUPEES
DIVIDEND OF 8 RUPEES PER SHARE
Source text for Eikon: ID:nBSE6DWGJ5
Further company coverage: HEST.NS
(([email protected];;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Hester Biosciences do?
Hester Biosciences Limited, a premier animal healthcare company in India known for poultry vaccines. Established in 1987, it has become a top global manufacturer with Asia's largest animal biological manufacturing unit in Ahmedabad.
Who are the competitors of Hester Biosciences?
Hester Biosciences major competitors are Themis Medicare, SMS Pharmaceuticals, Bajaj Healthcare, IOL Chem & Pharma, Shree Ganesh Remed., Kopran, NGL Fine-Chem. Market Cap of Hester Biosciences is ₹1,512 Crs. While the median market cap of its peers are ₹1,270 Crs.
Is Hester Biosciences financially stable compared to its competitors?
Hester Biosciences seems to be less financially stable compared to its competitors. Altman Z score of Hester Biosciences is 3.82 and is ranked 7 out of its 8 competitors.
Does Hester Biosciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Hester Biosciences latest dividend payout ratio is 27.02% and 3yr average dividend payout ratio is 24.74%
How has Hester Biosciences allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Hester Biosciences balance sheet?
Balance sheet of Hester Biosciences is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Hester Biosciences improving?
The profit is oscillating. The profit of Hester Biosciences is ₹30.41 Crs for TTM, ₹18.89 Crs for Mar 2024 and ₹26.63 Crs for Mar 2023.
Is the debt of Hester Biosciences increasing or decreasing?
Yes, The debt of Hester Biosciences is increasing. Latest debt of Hester Biosciences is ₹222 Crs as of Sep-24. This is greater than Mar-24 when it was ₹210 Crs.
Is Hester Biosciences stock expensive?
Hester Biosciences is not expensive. Latest PE of Hester Biosciences is 48.54, while 3 year average PE is 60.73. Also latest EV/EBITDA of Hester Biosciences is 30.01 while 3yr average is 33.38.
Has the share price of Hester Biosciences grown faster than its competition?
Hester Biosciences has given lower returns compared to its competitors. Hester Biosciences has grown at ~1.31% over the last 7yrs while peers have grown at a median rate of 16.2%
Is the promoter bullish about Hester Biosciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Hester Biosciences is 53.73% and last quarter promoter holding is 53.73%.
Are mutual funds buying/selling Hester Biosciences?
There is Insufficient data to gauge this.